MGI Pharma MOGN New patents, anti cancer Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: astro who wrote (1151)	12/24/1998 9:59:00 AM
From: David Cathcart	Read Replies (2) of 1826

The NCI has added a second non-small cell lung cancer PII trial: cancernet.nci.nih.gov The first NCI trial for non-small cell lung cancer was for advanced or recurrent cancer. The one is for recurrent or refractory non-small cell lung cancer. This is the fifth NCI sponsored PII trial. Every NCI sponsored trial is another opportunity for MGI-114 to demonstrate its efficacy and the only cost to MGI Pharma is that of supplying the drug. Such a deal. My MOGN predictions for 1999: Very encouraging efficacy in each of the company sponsored PII trials. The completion of the Euro deal and Blitzer will be the hero for sticking to his guns about not giving up US rights. Surging Salagen sales and a continuing profit in spite of the increasing MGI-114 development costs. A stock price of $40, and it could be double that if it looks like we will get fast track approval for pancreatic cancer. Merry Christmas everyone!!! David

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next